BSE Live
Apr 10, 16:01Prev. Close
59.37
Open Price
61.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Bacil Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -0.54 | -0.58 | -6.37 | 0.00 | -0.11 | |
| Diluted EPS (Rs.) | -0.54 | -0.58 | -6.37 | 0.00 | -0.11 | |
| Cash EPS (Rs.) | -0.47 | -0.51 | -5.73 | 0.00 | -0.10 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 2.12 | 2.93 | 3.43 | 9.86 | 9.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 2.12 | 2.93 | 3.43 | 9.86 | 9.80 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBDIT/Share (Rs.) | -0.47 | -0.51 | -0.07 | 0.00 | -0.10 | |
| PBIT/Share (Rs.) | -0.48 | -0.53 | -0.09 | 0.00 | -0.10 | |
| PBT/Share (Rs.) | -0.48 | -0.53 | -5.75 | 0.00 | -0.10 | |
| Net Profit/Share (Rs.) | -0.48 | -0.52 | -5.75 | 0.00 | -0.10 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Return on Networth / Equity (%) | -22.73 | -17.91 | -167.67 | -0.03 | -1.04 | |
| Return on Capital Employed (%) | -22.76 | -17.97 | -2.53 | -0.03 | -1.04 | |
| Return on Assets (%) | -7.67 | -7.51 | -78.92 | -0.03 | -1.00 | |
| Total Debt/Equity (X) | 0.12 | 0.05 | 0.00 | 0.05 | 0.04 | |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.02 | 1.16 | 1.46 | 19.34 | 0.85 | |
| Quick Ratio (X) | 1.02 | 1.16 | 1.46 | 19.34 | 0.85 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1.20 | 1.51 | 1.96 | 4.93 | 3.97 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | -3.91 | -4.51 | -42.24 | 4,212.70 | -59.87 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.78 | 0.79 | 1.00 | 0.73 | 0.58 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | -0.29 | -0.23 | -1.68 | 0.00 | -0.02 |
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth